The relationship between inflammation and fibrosis in IBD still remains unclear, but it has been described that PPARγ activation is able to downregulate pro-inflammatory cytokine production, such as IL-4, IL-5, and IL-6, and also inhibit profibrotic molecules, such as platelet-derived growth factor (PDGF), IL-1, and TGF-β, the main promoters of fibrosis (Vetuschi et al., 2018). Here, IL6 is linked to inflammatory bowel disease.